353 related articles for article (PubMed ID: 29393296)
1. Tamoxifen enhances stemness and promotes metastasis of ERα36
Wang Q; Jiang J; Ying G; Xie XQ; Zhang X; Xu W; Zhang X; Song E; Bu H; Ping YF; Yao XH; Wang B; Xu S; Yan ZX; Tai Y; Hu B; Qi X; Wang YX; He ZC; Wang Y; Wang JM; Cui YH; Chen F; Meng K; Wang Z; Bian XW
Cell Res; 2018 Mar; 28(3):336-358. PubMed ID: 29393296
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
3. From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression.
Chamard-Jovenin C; Jung AC; Chesnel A; Abecassis J; Flament S; Ledrappier S; Macabre C; Boukhobza T; Dumond H
BMC Syst Biol; 2015 Jun; 9():28. PubMed ID: 26080803
[TBL] [Abstract][Full Text] [Related]
4. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.
Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S
J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000
[TBL] [Abstract][Full Text] [Related]
5. 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer.
Garan LAW; Xiao Y; Lin WC
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2209211119. PubMed ID: 36252018
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen and ERα36: Fertilizing the seeds of breast cancer metastasis.
Burness ML; Wicha MS
Cell Res; 2018 Apr; 28(4):391-392. PubMed ID: 29563540
[No Abstract] [Full Text] [Related]
7. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
8. Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Muluhngwi P; Klinge CM
Mol Cell Endocrinol; 2017 Nov; 456():76-86. PubMed ID: 28163101
[TBL] [Abstract][Full Text] [Related]
9. Expression and localization of estrogen receptor in human breast cancer and its clinical significance.
Li L; Wang Q; Lv X; Sha L; Qin H; Wang L; Li L
Cell Biochem Biophys; 2015 Jan; 71(1):63-8. PubMed ID: 25113640
[TBL] [Abstract][Full Text] [Related]
10. Factors predictive of response to hormone therapy in breast cancer.
Rastelli F; Crispino S
Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
[TBL] [Abstract][Full Text] [Related]
11. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
13. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
Robertson JFR; Paridaens RJ; Lichfield J; Bradbury I; Campbell C
Eur J Cancer; 2021 Mar; 145():19-28. PubMed ID: 33418233
[TBL] [Abstract][Full Text] [Related]
14. The Role of ERα36 in Development and Tumor Malignancy.
Thiebaut C; Konan HP; Guerquin MJ; Chesnel A; Livera G; Le Romancer M; Dumond H
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526980
[TBL] [Abstract][Full Text] [Related]
15. SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity.
Zhang L; Gong C; Lau SL; Yang N; Wong OG; Cheung AN; Tsang JW; Chan KY; Khoo US
Cancer Res; 2013 Jan; 73(1):246-55. PubMed ID: 23117886
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
17. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.
Mansouri S; Farahmand L; Teymourzadeh A; Majidzadeh-A K
Curr Cancer Drug Targets; 2018; 18(7):668-676. PubMed ID: 28786348
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
Song T; Zhang H; Zhao Q; Hu Z; Wang Z; Song Y; Zhang Z
Breast Cancer Res; 2024 Feb; 26(1):33. PubMed ID: 38409088
[TBL] [Abstract][Full Text] [Related]
20. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
